SCM
SLXP

Suvretta Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Suvretta Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-133,000
Closed -$20.8M – 49
2014
Q3 		$20.8M Buy
+133,000
New +$19.3M 1.82% 25

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Suvretta Capital Management's SLXP Position: Q4 2014 in Review

Suvretta Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 133,000 shares — an estimated $20.8M sold.

Suvretta Capital Management first reported a position in SLXP in Q3 2014 and held it in 1 quarter. The position peaked at $20.8M in Q3 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Suvretta Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Suvretta Capital Management sold 133,000 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $20.8M.
  • Suvretta Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2014 and held it in 1 quarter.
  • Suvretta Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $20.8M in Q3 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Suvretta Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.